Viz.ai Partners With Vastrax to Accelerate Trial Enrollment and Illuminate to Improve Aortic Aneurysm Detection

November 16, 2022—Viz.ai, a developer of artificial intelligence (AI)–powered disease detection and intelligent care coordination, announced a strategic partnership with Vastrax, a vascular clinical research organization.

According to Viz.ai, it will work with Vastrax to help accelerate clinical trial enrollment for research on novel neurovascular therapies. The company’s Viz Recruit software will become Vastrax’s AI-powered clinical trial recruitment platform for its neurovascular trials.

The company stated that Viz Recruit, which has demonstrated 3 X 1 acceleration in clinical trial enrollment, identifies trial-eligible patients by scanning patient images in real-time, enabling around-the-clock, automatic identification of potential study patients with notifications sent to research teams. Viz.ai’s cloud-based technology broadens the recruitment funnel in both size and diversity and streamlines the trial enrollment workflow.

“Continued development of new technologies in neurointervention is the key to bringing better treatment options to patients and proving the safety and benefit of these technologies in the right patient population is fundamental to success,” commented Adnan H. Siddiqui, MD, in Viz.ai’s press release. “Viz.ai and Vastrax will enable accelerated and improved clinical trial enrollment and therefore quicker route to market for many new neurovascular devices.” Dr. Siddiqui, a leading clinical investigator in the neurointerventional field, is Vice Chairman in the Department of Neurosurgery at the State University of New York at Buffalo’s Jacobs School of Medicine and Biomedical Sciences in Buffalo, New York.

Additionally, on November 15, Viz.ai announced a partnership with Illuminate, Inc., a developer of natural language processing (NLP) and AI software that discovers at-risk patients from electronic medical records, assesses disease severity, and facilitates follow-up surveillance for a variety of diseases.

Viz.ai’s partnership with Illuminate will enable health care providers to make timely, critical decisions for aortic aneurysm patients while improving compliance with pre- and postsurgical surveillance programs.

According to Viz.ai, Illuminate’s NLP capability is a complement to the company’s growing platform, which will now offer health care systems a comprehensive solution to detect more suspected aortic aneurysms earlier and ensure that patients have access to the life-saving treatments or surveillance that they need by cross-functional care teams.

Illuminate’s Chief Medical Officer is Steven Okuhn, MD, a vascular surgeon at the San Francisco VA Medical Center in San Francisco, California.

“Aortic surveillance and screening programs are critical to ensuring that aortic aneurysm patients have their aortic aneurysms detected earlier so they get the care and follow-up that they need,” stated Dr. Okuhn in the Viz.ai press release. “Unfortunately, we have shown that patients often fall through the cracks in the care pathway.”

Dr. Okuhn continued, “This unique offering will help improve aortic aneurysm detection and patient workflow by bringing together natural language processing and image-based AI. I am incredibly excited about this clear advancement in aortic patient care.”